奥沙利铂联合雷替曲塞肝动脉灌注治疗中晚期肝细胞癌:II期单臂前瞻性研究
本研究为II期单臂前瞻性试验,评估肝动脉灌注奥沙利铂联合雷替曲塞治疗中晚期肝细胞癌的疗效与安全性。共纳入39例患者(34男5女,中位年龄53岁),符合方案人群客观缓解率为51.4%(18/35),意向治疗人群为46.2%(18/39)。未报告治疗相关IV级不良事件或死亡,III级不良事件包括AST升高(12.8%)等。结论认为该方案疗效有前景且毒性可接受,值得进一步评估。
要点
- 肝动脉灌注奥沙利铂联合雷替曲塞在中晚期肝细胞癌中显示有前景的疗效。
- 符合方案人群客观缓解率达51.4%,意向治疗人群为46.2%。
- 未报告治疗相关IV级不良事件或死亡,III级不良事件以AST升高为主。
核心结论
- 肝动脉灌注奥沙利铂联合雷替曲塞在中晚期肝细胞癌患者中显示出有前景的疗效和可接受的毒性水平,值得进一步评估。
研究设计与样本
- II期单臂前瞻性临床试验,采用Simon两阶段设计,纳入39例中晚期肝细胞癌患者(34男5女,中位年龄53岁),包括BCLC B期经TACE失败/难治及BCLC C期伴门静脉侵犯者。
主要发现
- 符合方案人群(35例)中18例(51.4%)达到客观缓解,意向治疗人群(39例)中18例(46.2%)达到客观缓解。
- 未报告治疗相关IV级不良事件或死亡;III级不良事件包括AST升高5例(12.8%)、ALT升高1例(2.6%)、白细胞减少1例(2.6%)、血小板减少1例(2.6%)和腹腔感染1例(2.6%)。
关键数值与推荐
- 客观缓解依据RECIST标准评估,符合方案人群为51.4%(18/35),意向治疗人群为46.2%(18/39)。
- 治疗每3周重复,直至疾病进展、不可接受毒性或患者拒绝继续治疗。
临床怎么用
- 对于BCLC B期TACE失败/难治或BCLC C期伴门静脉侵犯的中晚期肝细胞癌患者,可考虑肝动脉灌注奥沙利铂联合雷替曲塞作为治疗选择。
局限性
- 本研究为单臂II期试验,样本量较小(39例),缺乏对照组,结论需进一步随机对照研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the efficacy and safety of hepatic arterial infusion (HAI) of oxaliplatin plus raltitrexed in patients with intermediate stage and advanced stage hepatocellular carcinoma (HCC). METHODS: In this phase II, single-arm clinical trial, we enrolled patients aged 18-70 years with intermediate stage and advanced stage HCC, which included patients with HCC at Barcelona Clinic Liver Cancer (BCLC) stage B who experienced transcatheter arterial chemoembolization failure/refractoriness, and those with BCLC stage C with portal vein invasion. We performed HAI with oxaliplatin and raltitrexed. Treatment was repeated every 3 weeks and was discontinued either because of disease progression, unacceptable toxicity levels, or refusal of further treatment. We used Simon's two-stage design. The primary end-point was the objective response rate in accordance with the Response Evaluation Criteria in Solid Tumours. RESULTS: Fifty-one patients were screened between January 5, 2018 and August 7, 2019. Of these, 39 patients (34 men and 5 women; median age, 53 years) were enrolled and included in the intention-to-treat population. Objective response was achieved in 18 (51.4%) of 35 patients in the per-protocol population and in 18 (46.2%) of 39 patients in the intention-to-treat population. Treatment-related grade IV adverse events or deaths were not reported, and the observed grade III adverse events were elevated aspartate aminotransferase levels (5 [12.8%]), elevated alanine aminotransferase levels (1 [2.6%]), leukopenia (1 [2.6%]), thrombocytopaenia (1 [2.6%]) and abdominal infection (1 [2.6%]). CONCLUSION: HAI of oxaliplatin plus raltitrexed showed promising efficacy and acceptable toxicity levels in patients with intermediate and advanced stage HCC, and further evaluation is warranted.
引用
- Chen S, Zhang K, Liu W, et al. Hepatic arterial infusion of oxaliplatin plus raltitrexed in patients with intermediate and advanced stage hepatocellular carcinoma: A phase II, single-arm, prospective study. Eur J Cancer. 2020. PMID: 32497895. doi:10.1016/j.ejca.2020.03.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。